Sensus Healthcare (NASDAQ:SRTS) Shares Down 0.7% – Time to Sell?

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) dropped 0.7% on Friday. The stock traded as low as $2.93 and last traded at $2.95. 13,224 shares changed hands during trading, a decline of 44% from the average session volume of 23,533 shares. The stock had previously closed at $2.97.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SRTS shares. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.83.

Sensus Healthcare Price Performance

The company has a market cap of $48.56 million, a P/E ratio of -3.14 and a beta of 1.18. The company has a fifty day simple moving average of $3.11 and a 200-day simple moving average of $3.30.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

Insider Activity

In related news, Director Eric Sachetta bought 27,304 shares of Sensus Healthcare stock in a transaction dated Monday, August 31st. The stock was acquired at an average cost of $3.54 per share, with a total value of $96,656.16. Following the completion of the acquisition, the director directly owned 294,784 shares in the company, valued at approximately $1,043,535.36. This trade represents a 10.21% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 120,171 shares of company stock worth $405,230 over the last quarter. 10.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Sensus Healthcare

A number of institutional investors have recently bought and sold shares of SRTS. North Star Investment Management Corp. acquired a new stake in Sensus Healthcare during the 1st quarter worth about $500,000. Bank of New York Mellon Corp acquired a new position in shares of Sensus Healthcare in the second quarter worth $303,000. BlackRock Inc. acquired a new position in Sensus Healthcare in the 2nd quarter worth about $252,000. Finally, EP Wealth Advisors LLC bought a new position in Sensus Healthcare during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc (NASDAQ: SRTS) develops and markets non-invasive medical devices for dermatology and oncology. The company’s primary focus is superficial radiation therapy, a low-energy X-ray treatment designed to treat conditions affecting or located near the surface of the skin.

Its product portfolio includes the SRT-100 system and related platforms, which are used primarily in the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as keloid scars.